HuYON 007

Drug Profile

HuYON 007

Alternative Names: HuYON007; HuYON007 MultYbody™

Latest Information Update: 30 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator JN Biosciences
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action TRAIL receptor 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 May 2017 HuYON 007 is available for licensing as of 30 May 2017. http://www.jn-bio.com/pipeline (JN Biosciences pipeline, May 2017)
  • 23 May 2017 Preclinical trials in Cancer in USA (Parenteral) before May 2017 (JN Biosciences pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top